Halozyme Therapeutics (HALO) Capital Expenditures (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Capital Expenditures of $3.7 million for Q1 2026, up 293.79% year-over-year from $950000.0 in Q1 2025, and up 162.16% quarter-over-quarter from $1.4 million in Q4 2025.
Halozyme Therapeutics (HALO) Capital Expenditures (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Capital Expenditures for 17 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 293.79% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $9.8 million (up 521.64% YoY), while the FY2025 annual figure was $7.0 million, up 2389.29% from the prior year.
- Capital Expenditures rose to $3.7 million in Q1 2026 per HALO's latest filing, from $1.4 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $14.8 million in Q4 2023 and bottomed at -$7.4 million in Q4 2024.
- Historically, Capital Expenditures has averaged $1.8 million across 5 years, with a median of $1.1 million in 2022.
- On a YoY basis, Capital Expenditures climbed as much as 5957.38% in 2024 and fell as far as 1249.81% in 2024.
- Halozyme Therapeutics' Capital Expenditures stood at $2.3 million in 2022, then surged by 529.74% to $14.8 million in 2023, then tumbled by 149.89% to -$7.4 million in 2024, then soared by 119.38% to $1.4 million in 2025, then surged by 162.16% to $3.7 million in 2026.
- Business Quant data shows HALO's Capital Expenditures at $3.7 million in Q1 2026, $1.4 million in Q4 2025, and $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 4.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.17 Mn |
| Jun 30, 2026 | 4.17 Mn |
| Mar 31, 2026 | 3.74 Mn |
| Mar 31, 2026 | 3.74 Mn |
| Dec 31, 2025 | 1.43 Mn |
| Dec 31, 2025 | 1.43 Mn |
| Sep 30, 2025 | 3.03 Mn |
| Sep 30, 2025 | 3.03 Mn |
| Jun 30, 2025 | 1.56 Mn |
| Jun 30, 2025 | 1.56 Mn |
| Mar 31, 2025 | 950,000.00 |
| Mar 31, 2025 | 950,000.00 |
| Dec 31, 2024 | -7.36 Mn |
| Dec 31, 2024 | -7.36 Mn |
| Sep 30, 2024 | 7.15 Mn |
| Sep 30, 2024 | 7.15 Mn |
| Jun 30, 2024 | -3.05 Mn |
| Jun 30, 2024 | -3.05 Mn |
| Mar 31, 2024 | 3.55 Mn |
| Mar 31, 2024 | 3.55 Mn |